Vaccination programs and infectious disease burden among military personnel: a systematic review with pathogen-specific quantitative synthesis

Muhammad Sobri Maulana; Dwitia Pratiwi; Arditya Prayogi

doi:10.47353/ajmpm.v3i2.17

Authors

Muhammad Sobri Maulana RSAU Esnawan Antariksa Jakarta
Dwitia Pratiwi RSAU Esnawan Antariksa Jakarta
Arditya Prayogi UIN K.H. Abdurrahman Wahid Pekalongan

DOI:

https://doi.org/10.47353/ajmpm.v3i2.17

Keywords:

military personnel, vaccination program, infectious disease burden, adenovirus vaccine, influenza vaccine

Abstract

Introduction: Military personnel are highly exposed to vaccine-preventable infections because of close living conditions, rapid mobilization, deployment to endemic areas, and intense training schedules. This systematic review and meta-analysis evaluated whether vaccination programs reduce infectious disease burden among military personnel.

Methods: PubMed/MEDLINE, Embase, Cochrane Library, ProQuest, and Scopus were searched from database inception to 16 May 2026 for comparative studies of vaccination programs in military populations. Eligible outcomes were laboratory-confirmed infection, clinical disease, acute respiratory illness, meningococcal disease, or program-defined infectious disease burden. Random-effects meta-analysis was performed using log risk ratios.

Results: Sixteen studies were included in the qualitative synthesis and 13 contributed quantitative data. Across adenovirus, meningococcal, influenza, and COVID-19 vaccination programs, the pooled risk ratio was 0.19 (95% confidence interval 0.11-0.32), corresponding to an approximate 81% reduction in infectious disease burden. Subgroup effects were strongest for adenovirus and meningococcal vaccination programs and more moderate for influenza vaccination.

Discussion: The findings support vaccination as a high-impact readiness intervention in military settings, especially for pathogens amplified by recruit training environments. Certainty was limited by heterogeneity, pre-post designs, historical evidence, and inconsistent reporting of denominators.

Conclusion: Vaccination programs substantially reduce infectious disease burden among military personnel. Future research should use prospective surveillance, standardized case definitions, pathogen-specific laboratory confirmation, and transparent reporting of denominators and person-time.

Downloads

Download data is not yet available.

References

1. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71

2. Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. Syst Rev. 2021;10(1):39. doi:10.1186/s13643-020-01542-z

3. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.4. Cochrane; 2023.

4. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898

5. Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919

6. Grabenstein JD, Pittman PR, Greenwood JT, Engler RJM. Immunization to protect the US Armed Forces: heritage, current practice, and prospects. Epidemiol Rev. 2006;28(1):3-26. doi:10.1093/epirev/mxj003

7. Top FH Jr, Grossman RA, Bartelloni PJ, Segal HE, Dudding BA, Russell PK, et al. Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. J Infect Dis. 1971;124(2):148-154.

8. Top FH Jr, Dudding BA, Russell PK, Buescher EL. Control of respiratory disease in recruits with types 4 and 7 adenovirus vaccines. Am J Epidemiol. 1971;94(2):142-146.

9. Dudding BA, Top FH Jr, Winter PE, Buescher EL, Lamson TH, Leibovitz A. Acute respiratory disease in military trainees: the adenovirus surveillance experience. Am J Epidemiol. 1973;97(3):187-198.

10. Gaydos CA, Gaydos JC. Adenovirus vaccines in the U.S. military. Mil Med. 1995;160(6):300-304.

11. Russell KL, Hawksworth AW, Ryan MAK, Strickler J, Irvine M, Hansen CJ, et al. Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004. Vaccine. 2006;24(15):2835-2842.

12. Radigan KA, Binn LN, Snyder CE, Wagar EJ, Apicella MA, Gaydos JC. Safety and impact of adenovirus type 4 and type 7 vaccine live, oral in military recruits. Vaccine. 2016;34(38):4558-4564.

13. Earhart KC, Beadle C, Miller LK, Pruss MW, Gray GC, Ledbetter EK, et al. Outbreak of influenza in highly vaccinated crew of U.S. Navy ship. Emerg Infect Dis. 2001;7(3):463-465. doi:10.3201/eid0703.010320

14. Gray GC, Callahan JD, Hawksworth AW, Fisher CA, Gaydos JC. Respiratory diseases among U.S. military personnel: countering emerging threats. Emerg Infect Dis. 1999;5(3):379-385. doi:10.3201/eid0503.990308

15. Ryan MAK, Gray GC, Smith B, McKeehan JA, Hawksworth AW, Malasig MD. Large epidemic of respiratory illness due to adenovirus types 7 and 3 in healthy young adults. Clin Infect Dis. 2002;34(5):577-582.

16. Sanchez JL, Cooper MJ, Myers CA, Cummings JF, Vest KG, Russell KL. Respiratory infections in the U.S. military: recent experience and control. Mil Med. 2015;180(9):955-961.

17. Putnam SD, Gray GC, Biedenbender R, Hawksworth A, Burge R, Wierzba TF. Influenza vaccine effectiveness among military trainees during influenza seasons. Vaccine. 2010;28(10):2211-2216.

18. Krebs JW, Regan AK, Kaczmarek RG, Callahan JD, Strickler J. Seasonal influenza vaccination and respiratory illness in military populations. Mil Med. 2011;176(9):1024-1030.

19. Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Schneider H, Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970;282(8):417-420. doi:10.1056/NEJM197002192820801

20. Gold R, Artenstein MS. Meningococcal infections. II. Field trial of group C meningococcal polysaccharide vaccine in military recruits. Bull World Health Organ. 1971;45(3):279-282.

21. Brundage JF, Ryan MAK, Feighner BH, Erdtmann FJ. Meningococcal disease among United States military service members in relation to routine vaccination policies, 1971-1998. Clin Infect Dis. 2002;35(11):1376-1381.

22. Broderick MP, Faix DJ, Hansen CJ, Blair PJ. Meningococcal disease in the U.S. military: surveillance and prevention. Mil Med. 2003;168(8):620-624.

23. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344(18):1378-1388. doi:10.1056/NEJM200105033441807

24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. doi:10.1016/0197-2456(86)90046-2

25. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Chichester: John Wiley & Sons; 2009.

26. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560. doi:10.1136/bmj.327.7414.557

27. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2014.

28. Halloran ME, Longini IM, Struchiner CJ. Design and Analysis of Vaccine Studies. New York: Springer; 2010.

29. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577

30. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389

31. Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Prevention and attenuation of COVID-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021;385(4):320-329. doi:10.1056/NEJMoa2107058

32. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326(20):2043-2054. doi:10.1001/jama.2021.19499

33. Orenstein WA, Ahmed R. Simply put: vaccination saves lives. Proc Natl Acad Sci U S A. 2017;114(16):4031-4033. doi:10.1073/pnas.1704507114

34. Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ. 2008;86(2):140-146. doi:10.2471/BLT.07.040089